Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Downgrades Lilly to 'Near-Term Neutral'


Merrill Lynch downgraded Eli Lilly (LLY) to near-term neutral from buy.

Analyst Steven Tighe says Lilly shares have broken through his designated price objective of $57. He says, at the current price, Lilly shares are trading at a 31% premium to the S&P 500, and at a 25% premium to the drdug group, based on his 2003 estimated earnings of $2.75. With uncertainty remaining with regard to manufacturing in the near term, Tighe says he's concerned that the risk/reward profile for Lilly is becoming more balanced.

Tighe sees $2.61 2002 earnings per share, and maintains his long-term buy rating.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus